On the other hand, the remaining subtypes demonstrated specific therapeutic vulnerabilities; for example, SCLC-P was susceptible to PARP inhibitors, SCLC-N to AURK inhibitors, or SCLC-A to BCL-2 (B-cell leukemia/lymphoma, an apoptosis regulator protein) inhibitors. The gene discussed is BCL2; the disease is small cell lung carcinoma.